AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $229.98. The company's market cap stands at 406.64B, with a P/E ratio of 173.46 and a dividend yield of 2.9%.
On 2025-12-27, AbbVie(ABBV) stock moved within a range of $228.31 to $230.61. With shares now at $229.98, the stock is trading +0.7% above its intraday low and -0.3% below the session's peak.
Trading volume for AbbVie(ABBV) stock has reached 1.59M, versus its average volume of 5.86M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model ba...
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks This Holiday Season Unlock hedge-fund level data and powerful investin...
In one sense, there's no such thing as easy money. However, once you have money accumulated to invest, it can be easy to make more. That's the key to generating...
Analyst ratings
70%
of 30 ratingsMore ABBV News
In December 2025, OSE Immunotherapeutics announced it had amended its partnership with AbbVie on pre-clinical anti-inflammatory antibody ABBV-230, taking back r...
